U.S. News

Aventis Closer to U.S. Approval for AIDS-Related Drug

March 26, 2004

This article is part of The Body PRO's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document.

Paris-based Aventis, France's largest drug firm, is one step closer in getting U.S. approval for Sculptra, its injectable wrinkle-filling drug for patients with AIDS-related wasting condition. An advisory panel unanimously voted to recommend Food and Drug Administration approval of Sculptra for people with HIV, while cautioning against more widespread use. Aventis estimates annual sales of the drug to be as much as 1 billion euros (US$1.2 billion).

Back to other news for March 26, 2004

Adapted from:
New York Times
03.26.04; Bloomberg News

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.